We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Dirui Industrial

DIRUI Industrial Co., Ltd provides laboratory equipment and clinical diagnostic reagents for the in-vitro diagnostic ... read more Featured Products: More products

Download Mobile App

DIRUI Presents High-End Diagnostic Systems for Hospitals and High-Volume Labs at EUROMEDLAB 2022

By Carolyn Moody, RN - News Editor
Posted on 12 Apr 2022
Print article
Image: DIRUI presented its high-end analyzers at EUROMEDLAB (Photo courtesy of DIRUI)
Image: DIRUI presented its high-end analyzers at EUROMEDLAB (Photo courtesy of DIRUI)

DIRUI Industrial Co., Ltd. (Jilin, China) presented its high-end diagnostic systems, including hematology, chemiluminescence immunoassay, chemistry and urinanalysis analyzers, for hospitals and high-volume labs at EUROMEDLAB 2022.

DIRUI demonstrated its BF-7200Plus automatic hematology analysis system which has a maximum throughput of 480 tests per hour and measures 37 parameters (including RET detection), five scattergrams and two histograms. It performs optical analysis for WBC measurement and comes with pathology and morphology abnormality alarms. DIRUI also demonstrated its new CM180 chemiluminescence immunoassay analyzer with a throughput of up to 180 tests/hour and walk-away time of up to 2.5 hours. The CM180 has time to first result of only 15 minutes and allows 25 items to be tested at the same time. Featuring a user-friendly design to keep test results accurate and reliable, the CM180 analyzer provides the best solution for laboratory chemiluminescence immunoassay.

Also on display at EUROMEDLAB 2022 was DIRUI’s CS-T240Plus automatic chemistry analyzer which offers the ultimate in convenience, performance and confidence for small to medium size laboratories. The powerful desktop analyzer has a maximum throughput of 240 tests/hour at constant speed and 480 tests/hour for ISE. It uses whole blood samples to test for HbA1c, ensuring more accurate results and has a water consumption of only three liters per hour. This automated random access clinical chemistry analyzer can be easily integrated with any type of laboratories for routine, emergency analysis. In addition, DIRUI showcased its MUS-3600 automatic urinanalysis system with a flexible combination of modules and super fast detection speed. It has a throughput of up to 480 tests per hour (for hybrid) and allows up to 580 urine samples to be loaded at one time. Using leading detection methodologies, the MUS-3600 can provide objective and quantitative report information, clear and visible particle image information, and three key clinical information - red blood cell morphology information, urinary tract infection information, and urine culture information.

Related Links:
DIRUI Industrial Co., Ltd. 

Gold Supplier
Multichannel Pipettes
Finnpipette Novus
Infection Laboratory Test Panels
Carcinoembryonic Antigen Rapid Test
CEA Rapid Test Kit
Gold Supplier
CLIA Processor

Print article


Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: The new assay enables accurate prognosis and detection data for those prone to esophageal cancer (Photo courtesy of Previse)

First-of-Its-Kind Test Helps Determine Future Risk of Esophageal Cancer

Esophageal cancer is among the most lethal cancers in the world and has a 20% five-year survival rate post-diagnosis. Barrett's esophagus is the sole precursor known and is a significant risk factor for... Read more


view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more


view channel
Image: Sampling a single stool using multiple PCR panels can identify more pathogens rapidly (Photo courtesy of Pexels)

PCR Panels for Acute GI Infections Can Lower Costs, Hospitalization and Antibiotic Use

Acute gastroenteritis impacts adults across all age groups and incurs enormous healthcare expenses. Now, a new study comprising 40,000 hospital visits across various geographic locations has revealed that... Read more


view channel
Image: Artificial intelligence predicts genetics of cancerous brain tumors in under 90 seconds (Photo courtesy of Michigan Medicine)

AI-Based Diagnostic Screening System Predicts Genetics of Cancerous Brain Tumors in 90 Seconds

The diagnosis and treatment of gliomas increasingly rely on molecular classification, as surgical benefits and risks vary depending on a patient's genetic makeup. Complete removal of the tumor can extend... Read more


view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more


view channel
Image: Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel (Photo courtesy of Roche)

Roche and Eli Lilly Collaborate on Innovative Blood Test for Early Diagnosis of Alzheimer's

Presently, obstacles to timely and precise diagnosis of Alzheimer's disease exist globally, resulting in as many as 75% of individuals exhibiting symptoms but lacking a formal diagnosis.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.